![Françoise de Craecker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Françoise de Craecker
Direktor/Vorstandsmitglied bei X4 PHARMACEUTICALS, INC.
Vermögen: 97 634 $ am 31.05.2024
Aktive Positionen von Françoise de Craecker
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
RAPTOR PHARMACEUTICAL CORP | Corporate Officer/Principal | 01.01.2014 | - |
GENSIGHT BIOLOGICS S.A. | Direktor/Vorstandsmitglied | 16.05.2021 | - |
Independent Dir/Board Member | 16.05.2021 | - | |
X4 PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 14.10.2021 | - |
Independent Dir/Board Member | 14.10.2021 | - |
Karriereverlauf von Françoise de Craecker
Ehemalige bekannte Positionen von Françoise de Craecker
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AVEXIS INC | Corporate Officer/Principal | 01.01.2018 | 01.09.2019 |
Raptor Pharmaceuticals Europe BV
![]() Raptor Pharmaceuticals Europe BV Miscellaneous Commercial ServicesCommercial Services Part of Amgen, Inc., Raptor Pharmaceuticals Europe BV is a Dutch company that engages in research and experimental development in other physical and natural sciences. The company is based in Louveciennes, the Netherlands. | Corporate Officer/Principal | 01.07.2017 | 01.12.2017 |
Transkaryotic Therapies, Inc.
![]() Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Corporate Officer/Principal | 01.10.2000 | 01.03.2014 |
Ausbildung von Françoise de Craecker
Katholieke Universiteit Leuven | Graduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Belgien | 2 |
Frankreich | 2 |
Operativ
Corporate Officer/Principal | 4 |
Director/Board Member | 2 |
Independent Dir/Board Member | 2 |
Sektoral
Health Technology | 5 |
Commercial Services | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
GENSIGHT BIOLOGICS S.A. | Health Technology |
X4 PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Horizon Pharmaceutical LLC
![]() Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Novartis Gene Therapies, Inc.
![]() Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Raptor Pharmaceuticals Europe BV
![]() Raptor Pharmaceuticals Europe BV Miscellaneous Commercial ServicesCommercial Services Part of Amgen, Inc., Raptor Pharmaceuticals Europe BV is a Dutch company that engages in research and experimental development in other physical and natural sciences. The company is based in Louveciennes, the Netherlands. | Commercial Services |
Transkaryotic Therapies, Inc.
![]() Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
- Börse
- Insiders
- Françoise de Craecker
- Erfahrung